




**Biomedical**  
TRANSLATION BRIDGE  
PROGRAM

Powered by



**MTPConnect**  
MedTech and Pharma Growth Centre

In partnership with



# Biomedical Translation Bridge (BTB) Program

FREQUENTLY ASKED QUESTIONS  
COVID-19 CALL



Australian Government  
Department of Health  
Medical Research Future Fund

# Frequently Asked Questions

## What is the Biomedical Translation Bridge (BTB) Program?

The \$22.3 million BTB Program is an initiative of the Medical Research Future Fund (MRFF). In this specific COVID-19 call, the BTB program can provide up to \$1 million of funding to support eligible organisations developing medical devices, diagnostics, prophylactic or therapeutic approaches that can achieve an impact on the global response to the pandemic in less than 12-months.

The BTB program is led by MTPConnect, the Medical Technologies and Pharmaceuticals (MTP) Industry Growth Centre, in partnership with BioCurate (The University of Melbourne and Monash University), UniQuest (University of Queensland through its drug discovery initiative QEDDI), the Medical Device Partnering Program (MDPP, led by Flinders University) and the Bridge and BridgeTech programs through the Queensland University of Technology (QUT).

## What is MTPConnect?

MTPConnect is the Industry Growth Centre for the medical technology, biotechnology and pharmaceutical sector. As an independent, not-for-profit organisation MTPConnect champions a sector-led approach to accelerating the growth of Australia's MTP sector.

Since establishment in November 2015, MTPConnect has significantly impacted the MTP sector by delivering *Strategic Funding* to key initiatives, undertaking *Direct Action* and being the trusted and *Independent Voice* to inform government on key issues, challenges and opportunities.

Through the Department of Industry, Innovation and Science's Growth Centre Project Fund, MTPConnect has committed \$15.6 million across 36 collaborative projects, engaging over 160 consortium members and leveraging \$22 million of matched cash funding from industry. In addition to the BTB program, MTPConnect also operates the MRFF's BioMedTech Horizons program which currently supports 20 projects and will deploy an additional \$25 million over the next three years.

## What is BioCurate?

BioCurate is an independently operated joint venture of the University of Melbourne and Monash University, supported by the Victorian State Government, to propel important discoveries out of the lab to generate new therapies.

BioCurate aims to be a recognised global leader in the translation of basic medical research into human therapeutics. Our mission is to grow the Victorian and Australian biotech sector by translating medical research outputs into high quality pre-clinical candidates for the bio-pharmaceutical industry, venture capital companies and philanthropic funding agencies.

BioCurate specifically addresses the barriers that limit the translation and commercialisation of early stage research, thereby increasing the quantity and quality of discovery projects progressing to a new drug therapy and providing benefits to patients. BioCurate provides the commercial focus, expertise and funding necessary to address these barriers to success, and drive early decisions, with the intent of boosting the successful development of new medicines. Strong and collaborative linkages are well progressed with the Universities and other key partners in health, research and industry in Australia and internationally.

### **What is UniQuest and QEDDI?**

UniQuest is a leading university-based commercialisation office, managing the intellectual property of The University of Queensland. Since 1984, it has created more than 100 startups based on UQ research and raised more than \$700 million. UniQuest benchmarks in the top five per cent globally for university commercialisation, generating more licence income than the other Group of Eight universities. UniQuest manages an extensive intellectual property portfolio, including the HPV vaccine Gardasil. Gross sales of products licensed by UniQuest have surpassed \$US32 billion. More than \$655 million in revenue has been returned to UQ.

The Queensland Emory Drug Discovery Initiative (QEDDI), a division of UniQuest, is a small molecule drug discovery and development facility translating The University of Queensland and collaborator's biomedical research into new medicines to deliver faster health benefits. QEDDI will translate drug target biology or small molecule hits/leads into lead molecules/drug candidates using medicinal chemistry with the ultimate aim of a commercial outcome. By advancing academic research to novel molecules it is expected to increase the probability of the research striking a commercialisation partnership at increased commercial terms.

### **What is the Medical Device Partnering Program?**

The Medical Device Partnering Program (MDPP) is an ideas incubator driving entrepreneurial culture within the medtech sector. MDPP fosters collaborations between researchers, industry, end-users and government and develops novel medical devices with global market potential.

MDPP forms the essential links between clinical need and knowledge with technical expertise and industry know how. As such, the program is a key enabler for the sector, building the bridge to connect bench to bedside and supporting ideas to the proof-of-concept and prototypes that are required to drive engagement with industry and end users.

MDPP is a national initiative working closely with more than 30 partners across Australia, including research organisations, health networks, accelerators, service providers and funding bodies.

### **What are the Bridge and BridgeTech Programs?**

The Bridge and BridgeTech Programs, facilitated and hosted by QUT, are nation-wide collaborative commercialisation training programs.

The Bridge program provides commercialisation training focused on the pharmaceutical sector in collaboration with 10 University and pharmaceutical industry partners. Now in its third year, Bridge selects up to 100 participants each year from around Australia.

The BridgeTech program provides industry focused commercialisation training for the medtech-medical devices sector in collaboration with 20 university and industry sector partners. Now in its second year, BridgeTech selects up to 80 participants annually to focus on training for the medical technology, devices and diagnostic industries.

Both programs aim to improve the skills and capabilities of Australia's life science entrepreneurs, researchers and scientists, to improve the quality and quantity of commercial deals and deepen collaboration between Australian researchers and the relevant industry sectors.

## Offerings and Focus

### **Does the BTB Program have a specific disease or therapeutic focus?**

Normally, the BTB Program is agnostic as to human disease area and will accept applications that address all disease areas and any therapeutic modality. However, in response to the current pandemic, Round 3 will be focused on medical research addressing COVID-19 related unmet medical needs.

### **What type of projects are funded?**

The BTB Program will fund research and development projects to progress prophylactics, therapeutics, or medical devices to achieve an impact on the global response to the pandemic in less than 12-months. There must be a clear value proposition for the proposed product and differentiating features from currently available solutions or those in development globally.

### **What definition is used for medical devices?**

All kinds of medical devices are eligible under the BTB Program including hospital equipment, surgical instrumentation, implantables, diagnostic devices (including in vitro diagnostics), therapeutic devices, assistive technologies, clinic software, personal devices and apps, and medical simulators. However, a preference is given to those that meet the definition and are regulated under the Therapeutic Goods Administration.

The BTB Program accepts applications for technologies at Technology Readiness Levels 3 – 7. We require evidence of research that clearly identifies the problem or the possibility of the technological solution.

### **What projects are out of scope for the BTB Program?**

In Round 3, projects that do not address the COVID-19 unmet need are not eligible.

Other exclusions to this funding round include, but are not limited to:

- Personal protective equipment (PPE), its manufacturing or other infection control practices
- Modelling and visual representations of epidemiological information.
- Public and population health analyses.

Projects to develop databases, animal models, non-human health programs that could then be commercialised are not eligible. Ideas or concepts alone are not accepted by the BTB Program. There must be evidence of research that has been undertaken that validates the technology.

### **How does the BTB panel decide on what projects to fund?**

Expressions of Interest (EOI) and Stage 2 Proposals that meet the eligibility criteria set out in the Program Guidelines ([BTB website](#)) will be assessed by expert review panels against defined selection criteria that address several technical, financial, development and impact factors. The projects will need to be viable and demonstrate a good probability of leading to a public good outcome in the BTB timeline. Projects will need to provide clear differentiation from current solutions or those in development globally.

## **Selection Criteria**

### **Where do I find the Selection Criteria?**

An indicative list of selection criteria for all projects are detailed in the Program Guidelines which can be found on the [BTB website](#).

### **Are the Selection Criteria applicable to all eligible projects and will they be published on the website?**

The Selection Criteria and Program Guidelines are detailed on the [BTB website](#). Selection criteria may vary slightly between BTB funding rounds and according to therapeutic modality or medical device type and application.

### **What is expected of an inventor or lead investigator?**

We anticipate the Applicant and its research team are willing to participate in mentorship and engage constructively with the advice and support process provided by the BTB Venture Partners.

### **What are the expectations with respect to experimental data?**

Experimental, ideally randomised, blinded and controlled (positive, negative) with standard of care or gold standard comparator where possible. Ideally reproducible at independent sites, or within your own group with appropriate design and control measures. Projects should not be based purely on published, non-validated data.

## **Eligibility Criteria**

### **Where do I find the Eligibility Criteria?**

The Eligibility Criteria are detailed within the Program Guidelines and can be found on the [BTB website](#).

### **Who can apply?**

Entities eligible for funding under the BTB Program are defined in s24 of the [Medical Research Future Fund Act 2015](#) and include:

- a medical research institute;
- a university;
- a corporate Commonwealth entity;
- a corporation.

Applicants must have an Australian Business Number (ABN).

### **I have a spin-out company with seed funding and previously invested capital. If our application is accepted, are the expenses we have already incurred viewed as eligible expenses or as matching contributions?**

No, expenses must be incurred during the term of the project.

### **Can a multinational company be a partner of an Australian applicant?**

Multinational companies can be partners in an application with an eligible Australian entity. Matching funding can come from any source provided it does not come from a federal government-funded program.

### **Do the projects have to be submitted through an institution or solely through an SME or could it be both?**

It can be any of the above. The SME or institution must provide the matching funding.

## **Expressions of Interest (EOI)**

### **Where do I find the EOI form?**

Submission of an EOI must be made online through SmartyGrants, the [online application portal](#).

### **How will EOIs be matched with UniQuest, BioCurate or MDPP?**

Eligible EOIs that are successful in passing through expert review will be matched with one of our three Venture Partners taking into account our partners' expertise and any previous interactions the applicants have had with one or more of our partners.

### **Can I submit an EOI for a project that I have already submitted as an application to another granting body such as the NHMRC or to another government funding source?**

The BTB Program will accept applications for projects that have already been submitted to other funding sources. However, the BTB Program will not fund programs that are already funded by an alternative source. Should your application to an alternative funding source be successful, the BTB application/funding will be discontinued.

### **If my application was unsuccessful in a previous BTB Round, can I resubmit in Round 3?**

Unsuccessful applicants are encouraged to re-apply in subsequent rounds once any shortcomings identified by the review panels in previous applications are shown to have been adequately addressed.

### **Can big pharma be partners of the SME applicants?**

The funding needs to be in cash and can come from big pharma coming through eligible entities. The IP would need to reside with the applicant, which would not be the big pharma partner.

### **What would the ranking of projects look like?**

Projects with more validation and a clear development path to achieve an impact on the global response to the pandemic within 12 months will be ranked higher and will be more likely to receive funding.

### **Can Venture Capital provide the matching funding?**

Yes.



### **How can I substantiate my claims while maximising the word count?**

The EOI stage is brief, you need to hook the assessors with a clear story line while substantiating any claims with data or reference to data. You will have the opportunity to expand on your project in the final Stage 2 Proposal. Assessors will cast a critical eye over your data package to ensure that it is robust and reliable – appropriately controlled, benchmarked, reproducible.

Below is a set of examples on how to maximise word count while referencing outcomes:

- Our lead compound kills breast cancer cells in an in vitro model – 12 words
- Our lead reduces MCF7 cell viability by 98% in vitro – 10 words
- Lead activity-in vitro (MCF7-Growth Inhibition): Emax-98%, EC50-10µM, 8-point titration – **9 words!**

## **Funding**

### **How much funding is available for my project?**

Successful applicants to the BTB Program can receive up to \$1 million of matching funding for a maximum of 12 months. Applicants will be required to provide one-to-one matching funding (cash) to be eligible.

### **Can any of the funds be spent overseas or do they need to be spent in Australia?**

Funding from the BTB Program must be spent in Australia. However, overseas expenditures may be approved on a case-by-case basis where applicants can clearly demonstrate that the specific expertise or activity required to progress a project can't be accessed or completed from within Australia.

### **I don't have the matching funding now, but I am confident that I will have it soon. Am I eligible for the BTB program?**

Applicants are required to demonstrate that they have matching funding available at the time of EOI submission. Payments from the BTB program are paid in arrears upon achieving defined and agreed milestones. Applicants must demonstrate that they have contributed an equal or greater amount of funding within each milestone.

### **If I have government funding as matching funding am I eligible?**

Federal funding is not eligible as matched cash. Some State-based funding may be eligible and will be considered on a case by case basis. Universities, MRIs and foundations may contribute matching funding from non-government sources of revenue.

### **Can international grants be considered as matched funding?**

This would be assessed on a case-by-case basis. International capital source is eligible.

### **Is crowd funding/family and friend's investment considered matching funding?**

Yes, all non-government sources of matching cash are acceptable. However, programs will be assessed based upon their ability to demonstrate adequate matching capital.



### **At what point is matching funding required?**

Matched funding must be available at the time of submitting the EOI. To demonstrate this, a formal letter of commitment is required with the EOI application.

### **Can I change sources of matching funding during the Program?**

This would be assessed on a case by case basis.

### **What evidence of matching funding do I need to provide?**

Financial Letter(s) of Support must be uploaded as part of the EOI application to provide an assurance from the organisation that matched funding is available. The Letter(s) of Support should outline what is being contributed and if this is cash or in-kind, be on the organisation's letterhead, and signed by an appropriate authorised individual. More than one organisation can contribute to the matched cash component. Once a project is awarded funding, the funding will be paid in arrears. Successful applicants will need to provide copies of receipts for eligible expenditures before the BTB Program can make payments.

### **Is there a time period for which money has to be spent if awarded?**

Projects submitted in Round 3 have a maximum 12-month term and must be completed by 31 August 2021.

### **What range of investment will likely be awarded?**

\$200,000 to \$1million to be matched. Award amounts for less than \$200,000 will be considered on a case-by-case basis.

## **Intellectual Property Management and Commercialisation**

### **How will Intellectual Property be protected during the application and funding process?**

EOIs are disclosed on a non-confidential basis and should not contain any enabling data or material. Confidentiality Disclosure Agreements may be entered into with applicants whose projects move beyond the EOI stage to allow for a complete review and assessment of your project.

### **Who owns the Intellectual Property?**

All IP related to the project defined in the EOI and Stage 2 Proposal is owned by the applicant, subject to any arrangements it has with third parties (eg. CROs). If MTPConnect or its partners creates IP as part of the Proposal review or mentorship process, the IP will be owned by the applicant. Inventorship will be determined based on standard protocols.

### **If IP is generated as part of a funded project that is saleable to an overseas interest, would that be permitted?**

Yes.

### **Who pays for patent applications?**

Patenting/protection of the IP will be the responsibility of the successful applicant, but IP expenses are eligible expenditure under the terms of the BTB funding agreement.

### **What happens to my project when it has received the maximum BTB funding but still requires further development and funding?**

The BTB Program can provide up to \$1 million of matching funding during the project term. Upon completion of the program, applicants must seek other sources of funding.

### **Will MTPConnect and/or Venture Partners require a return on BTB investment?**

No. Venture Partner involvement in the BTB mechanism is on a service basis. If a Venture Partner and applicant enter into a commercial arrangement at the end of a BTB funded project, then any requirement for return on subsequent investment after the end of the funding period will be negotiated outside of the BTB mechanism.

## **Connecting with the BTB Team**

Further questions can be directed to:

Lauren Kelly, Director Biomedical Translation Bridge Program:  
[lauren.kelly@mtpconnect.org.au](mailto:lauren.kelly@mtpconnect.org.au)

Check the [BTB website](#) for updates.